Table 1.
Demographic summary of the study cohort
| Aβ-negative/tau-negative | Aβ-positive/tau-negative | Aβ-positive/tau-positive | |
|---|---|---|---|
| n (% female) | 238 (64%) | 100 (57%) | 86 (50%) |
| Age | 72 (5) | 73 (5) | 73 (5) |
| Years of education | 13 (3) | 12 (4)c | 12 (3)c |
| APOE ɛ4 (%) | 45 (19%) | 64 (64%)c | 60 (70%)c |
| MMSE | 29 (1) | 28 (2)c | 27 (2) c |
| mPACC | 0.0 (0.6) | −0.8 (1.1)c | −1.4 (1.2)c |
| Trail Making Test-Aa | 45 (16) | 53 (25)c | 58 (30)c |
| Trail Making Test-Ba | 91 (34) | 119 (62)c | 111 (35)c |
| ADAS delayed recall | 2 (2) | 4 (3)c | 6 (3)c |
| CSF Aβ42/Aβ40 | 0.096 (0.015) | 0.049 (0.011)c | 0.038 (0.009)c |
| CSF p-tau181b | 16 (4) | 20 (5)c | 38 (9)c |
Values are given as mean (standard deviation). Aβ-positive/negative defined based on a CSF Aβ42/Aβ40 of less than 0.066.17 Tau positivity was defined as 2 standard deviations from the mean p-tau181 level of the cognitively unimpaired Aβ-negative participants. Aβ = amyloid-β; ADAS = Alzheimer’s Disease Assessment Scale; MMSE = Mini-Mental State Examination; mPACC = modified version of the Preclinical Alzheimer Cognitive Composite.
aThe scores for the Trail Making Tests are reported in seconds.
bCSF p-tau181 levels are reported in pg/ml. Both cognitive and biomarkers values refer to baseline measures.
cSignificantly different from the Aβ-negative/tau-negative (P < 0.05).